Bisphosphonates in metastatic bone disease: Renal safety matters

Oncologist

Volumn 10, Issue SUPPL. 1, 2005, Pages 1-2

  Body, Jean Jacques ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Advanced cancer; Bisphosphonates; Bone metastases; Ibandronate; Renal safety

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE METASTASIS; CONFERENCE PAPER; DRUG SAFETY; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 27144519167     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-1-1     Document Type: Conference Paper

References (12)

1. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.
2. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
3. Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors study group. J Clin Oncol 2003;21:3150-3157.
4. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
5. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679.
6. Diel I, Body JJ, Bergström B. Renal safety of intravenous (i.v) ibandronate for up to 4 years of treatment in patients with metastatic bone disease. Ann Oncol 2004;15(suppl 3):iii224.
7. Heidenreich A, Ohlmann C, Olbert P et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 2003;1(suppl 5):S270.
8. Ohlmann C, Heidenreich A. Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Support Care Cancer 2003;11:396.
9. Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. The Oncologist 2005;10(suppl 1):3-7.
10. Bell R. Efficacy of ibandronate in metastatic bone disease: review of clinical data. The Oncologist 2005;10(suppl 1):8-13.
11. Jackson GH. Renal safety of ibandronate. The Oncologist 2005;10(suppl 1):14-18.
12. von Moos R. Bisphosphonate treatment recommendations for oncologists. The Oncologist 2005;10(suppl 1):19-24.